Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04681105
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:32.548683+00:00
Published At
2026-01-28T00:00:00+00:00
Record Updated At
2026-01-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Recurrent Acute Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hairy Cell Leukemia", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory Acute Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Hairy Cell Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory T Acute Lymphoblastic Leukemia", "Systemic Mastocytosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-28"
protocolSection.identificationModule.nctId
"NCT04681105"
protocolSection.identificationModule.officialTitle
"A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Recurrent Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Recurrent Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Hematologic Malignancy (protocolSection.conditionsModule.conditions)
  • Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent T Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Refractory Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Hematologic Malignancy (protocolSection.conditionsModule.conditions)
  • Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory T Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Systemic Mastocytosis (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.